- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01416766
CONtrolling Disease Using Inexpensive IT - Hypertension in Diabetes (CONDUIT-HID)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Worcester, Massachusetts, United States, 01605
- Reliant Medical Group
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- diagnoses of both diabetes mellitus (MODIFICATION 2/13: prediabetes) and hypertension
- uncontrolled hypertension (mean of up to most recent 3 clinic BPs in previous 6 months with SBP>=145 and/or DBP>=85) AND mean of 3 readings taken at intake visit meeting same criterion
Exclusion Criteria:
- end-stage renal disease
- management of blood pressure by provider other than primary care provider (PCP)
- pregnancy/gestational diabetes
- terminal illness
- diagnosed or probable (based on screen) dementia
- active psychosis
- moderate-severe mental retardation
- indication by PCP that patient would be inappropriate for study
- planning to leave Reliant Medical Group (formerly Fallon Clinic) during the coming year
MODIFICATIONS: due to a smaller pool of eligible participants and lower enrollment than anticipated, eligibility for the study has been expanded as of February 2013 to include persons with "prediabetes," defined by either a coded diagnosis of abnormal glucose (International Classification of Diseases [ICD] 9-CM codes 790.2x) or a hemoglobin A1c laboratory value from 6.0%-6.4%. For this group, the DBP eligibility criterion will be a mean, as defined above, of >=95, as target BP for this group is 140/90, not 140/80.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Control
Control participants will receive usual care during their year of enrollment.
At enrollment, prior to randomization, they will be informed that, if randomized to control status, they will be offered a free BP monitor and the opportunity to receive the study intervention after completing the exit interview in 1 year.
|
|
|
Experimental: Intervention
Self-monitoring-nurse-primary care provider feedback loop After randomization, intervention participants will receive the intervention (free home BP monitor, assistance setting up to upload BP readings from home/work or clinic computer; feedback loop with nurse-driven protocols to manage uncontrolled hypertension and maintain control once attained).
|
Intervention participants will receive an Omron BP monitor and assistance in setting it up to upload BP data to Reliant Medical Group from a home/work or clinic-based computer.
They will be encouraged to upload readings at least once/month.
Diabetes management nurses will receive the readings and, if a participant's mean BP is not at target, will follow protocols to address this, contacting PCPs as indicated by protocols.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in blood pressure (BP)
Time Frame: At entry (day 1) and 1 year later; secondarily, electronic health record (EHR)-based readings prior to entry and one year later
|
We will assess differences in changes in systolic BP (SBP) and diastolic BP (DBP) measured at study intake and 1 year later at exit.
We will also evaluate changes in mean EHR BP readings prior to study entry and in the 3 months before study exit.
We will also assess the primary outcome in terms of % of intervention vs. control participants achieving control (originally proposed as mean of 3 exit readings <130 SBP and 80 DBP but now revised to 140 SBP and 80 DBP due to new evidence and change in the Healthcare Effectiveness Data and Information Set (HEDIS) measure for 2011).
NOTE: For eligible participant group added 2/13, "prediabetic" patients, DBP control will be judged as mean <90mmHg as target BP for these groups is 140/90.
|
At entry (day 1) and 1 year later; secondarily, electronic health record (EHR)-based readings prior to entry and one year later
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Refill adherence
Time Frame: 6 months prior to study entry and 6 months prior to study exit
|
We will compare changes in the Medication Possession Ratio for antihypertensive medications for the 6 months prior to study entry and the 6 months prior to study exit for the subset of participants for whom insurance claims give us complete data on prescription fills.
|
6 months prior to study entry and 6 months prior to study exit
|
|
Self-reported medication adherence
Time Frame: At entry (day 1) and 1 year later, at exit
|
Change in self-reported medication adherence, based on: 1) the modified Morisky scale and 2) a visual analog scale (Walsh).
|
At entry (day 1) and 1 year later, at exit
|
|
Technology use
Time Frame: Continuous over course of study; final measurement at exit interview for intervention subjects & 6 mos. after exit for controls
|
We will measure use of home/office/other personal computers to upload BP readings over the internet vs. bringing BP monitor to clinic and uploading data vs. calling/mailing/faxing readings (offered to those not doing either of the first 2 after 2-3 months).
We intend to offer delayed entry after the exit to control subjects and will assess their use over the next 3-6 months.
|
Continuous over course of study; final measurement at exit interview for intervention subjects & 6 mos. after exit for controls
|
|
Health care utilization
Time Frame: Enrollment through exit 1 year later
|
We will measure counts of Reliant Medical Group visits and hospitalizations.
Number of antihypertensive medications and post/pre change will be compared for control vs. intervention participants.
We will also compare health care costs, as represented by billed charges; complete charges are expected to be available for ~70% of participants; clinic-only charges will be compared for the remainder.
|
Enrollment through exit 1 year later
|
|
Satisfaction
Time Frame: At entry (day 1) and 1 year later, at exit
|
Participant satisfaction with care will be measured using Consumer Assessment of Healthcare Providers and Systems (CAHPS) clinician and group survey questions.
|
At entry (day 1) and 1 year later, at exit
|
Collaborators and Investigators
Investigators
- Principal Investigator: Barry G Saver, MD, MPH, University of Massachusetts, Worcester
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CONDUIT-001
- R18HS018461 (U.S. AHRQ Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
Franz Rischard, DOAcceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway...Not yet recruitingPulmonary Hypertension | Pulmonary Arterial Hypertension (PAH)United States
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
Abant Izzet Baysal UniversityNot yet recruitingPRIMARY HYPERTENSIONTurkey (Türkiye)
-
SingHealth PolyclinicsNanyang PolytechnicEnrolling by invitationHypertension,EssentialSingapore
-
Hacettepe UniversityBozok UniversityCompletedHypertension | Arterial Hypertension | Systemic HypertensionTurkey (Türkiye)
-
BackBeat Medical IncNot yet recruitingHypertension, Systolic | Hypertension (HTN) | Heart Failure With Preserved Ejection Fraction (HFpEFGeorgia
-
Xuanwu Hospital, BeijingNot yet recruiting
-
Shenzhen Salubris Pharmaceuticals Co., Ltd.Not yet recruiting
-
Instituto de Cardiologia do Rio Grande do SulCompletedHypertension (HTN) | Hypertension ArterialBrazil
Clinical Trials on Self-monitoring-nurse-primary care provider feedback loop
-
MedStar Georgetown University HospitalMedstar Health Research InstituteUnknownHypertension | Ischemic StrokeUnited States
-
Debra MoserUniversity of Kentucky Center for Excellence in Rural Health-HazardCompletedDepression | Hypertension | Obesity | HyperlipidemiaUnited States
-
UMC UtrechtRijnstate HospitalCompletedCardiovascular DiseasesNetherlands
-
Radboud University Medical CenterMcGill University; Erasmus Medical Center; ZonMw: The Netherlands Organisation... and other collaboratorsCompletedLung Diseases, ObstructiveNetherlands
-
University of California, San FranciscoUrban Institute; Laura and John Arnold Foundation; Feeding AmericaCompletedDiabetes MellitusUnited States
-
Tulane UniversityNational Heart, Lung, and Blood Institute (NHLBI)Recruiting
-
University of PittsburghAgency for Healthcare Research and Quality (AHRQ)CompletedBody Weight | Weight Loss | Motor ActivityUnited States
-
San Diego State UniversityNational Institute on Minority Health and Health Disparities (NIMHD); Family...RecruitingLow Back Pain | Neck PainUnited States
-
University of WashingtonNational Institute on Drug Abuse (NIDA); Kaiser PermanenteCompleted
-
University of California, Los AngelesNational Institute on Drug Abuse (NIDA); Medical University of South Carolina; University of ArkansasActive, not recruitingDrug UseUnited States